Obesity, metabolic syndrome, and inflammation: An update for anaesthetists caring for patients with obesity.
Anaesth Crit Care Pain Med
; 40(6): 100947, 2021 12.
Article
en En
| MEDLINE
| ID: mdl-34534700
ABSTRACT
Our understanding of chronic inflammation in obesity is evolving. Suggested mechanisms include hypoxia of adipose tissue and a subsequent increase in circulating cytokines. It is now known that adipose tissue, far from being an inert tissue, produces and secretes multiple peptides that influence inflammation and metabolism, including substrates of the renin-angiotensin-aldosterone system (RAAS). RAAS blocking antihypertensive medication and cholesterol-lowering agents are now being evaluated for their metabolic and inflammation-modulating effects. Surgery also has pro-inflammatory effects, which may be exacerbated in patients with obesity. This narrative review will summarise the recent literature surrounding obesity, metabolic syndrome, inflammation, and interplay with the RAAS, with evidence-based recommendations for the optimisation of patients with obesity, prior to surgery and anaesthesia.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Síndrome Metabólico
Límite:
Humans
Idioma:
En
Revista:
Anaesth Crit Care Pain Med
Año:
2021
Tipo del documento:
Article